Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01214603
NCT01214603CompletedPhase 2

A Phase 2 Study of LY2090314 in Participants With Acute Leukemia

Eli Lilly and Company1 site in 1 country20 target enrollmentStarted: November 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
20
Locations
1
Primary Endpoint
Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is a multicenter, non-randomized, open-label, Phase 2 study of intravenous LY2090314 in participants with acute leukemia.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Participants must have confirmed diagnosis of one of the following:
  • •Acute myelogenous leukemia (AML) that is refractory or relapsed disease. If participants have acute promyelocytic leukemia (APL), they must have received prior all-trans retinoic acid and arsenic trioxide unless ineligible or intolerant to them
  • •Untreated AML (de novo or arising from a myelodysplastic syndrome). In the opinion of the investigator, the participant should not be a candidate for standard therapy and a clinical trial is a preferred treatment option
  • •Have given written informed consent prior to any study-specific procedures
  • •Have adequate organ function including:
  • •Hepatic: Bilirubin less than or equal to 1.5 times the upper limit of normal (ULN). Alkaline phosphatase (ALP) and transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] less than or equal to 5 times ULN
  • •Renal: Serum creatinine less than or equal to the ULN. No known active renal disease. In rare cases, participants may enter treatment with a serum creatinine greater than the ULN as elevations of serum creatinine may be secondary to dehydration
  • •Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale
  • •Have discontinued all previous approved therapies for acute leukemia, including chemotherapy for at least 14 days, and recovered from the acute effects of therapy. Hydroxyurea used to control peripheral blast count is permitted within the first 2 cycles of treatment on study, but it must be stopped at least 24 hours before study drug administration in Cycle 3
  • •Are reliable and willing to be available for the duration of the study and are willing to follow study procedures
  • •Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug
  • •Females with childbearing potential must have had a negative urine or serum pregnancy test less than or equal to 7 days prior to the first dose of study drug
  • •Have an estimated life expectancy of greater than or equal to 6 weeks

Exclusion Criteria

  • •Have received treatment within 14 days of the initial dose of study drug with an experimental agent for noncancer indications that has not received regulatory approval for any indication
  • •Participants with chronic myelogenous leukemia (CML) including blast crisis phase
  • •Participants with known central nervous system (CNS) leukemia by spinal fluid cytology or imaging
  • •Have serious pre-existing medical conditions (left to the discretion of the investigator)
  • •Have one of the following abnormalities: QTc (Fridericia corrected) interval >450 milliseconds (msec) on screening electrocardiogram (ECG), previous history of QTc prolongation with another medication that required discontinuation, congenital long QT syndrome, previous history of ventricular tachycardia or unexplained syncope, left bundle branch block, or chronic atrial fibrillation
  • •Have family history of long QT syndrome or sudden death due to ventricular arrhythmia
  • •Concomitant medication that may cause QTc prolongation or induce Torsades de Pointes at the time of study entry
  • •Have systolic blood pressure greater than or equal to 160 millimeter of mercury (mm Hg) and diastolic blood pressure greater than or equal to 100 mm Hg
  • •Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class II or higher or participants with a history of arrhythmia that is symptomatic or requires treatment
  • •Have uncorrected electrolyte disorders including potassium
  • •Have other active malignancy (with the exception of basal and squamous cell skin cancer) at time of study entry
  • •Have received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug
  • •Have uncontrolled systemic infection
  • •Females who are pregnant or lactating
  • •Presence of clinical evidence of viral disease caused by human immunodeficiency virus, hepatitis B, or hepatitis C

Arms & Interventions

LY2090314

Experimental

Cohort 1: 40 milligrams (mg) LY2090314 administered on Days 1, 8, and 15 of a 28-day cycle for at least two (2) 28-day cycles. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met.

Due to a protocol amendment on September 2010, the study added 2 additional treatment schedules/cohorts. Cohort 2: 40 mg dose given on Days 1, 5, and 9 of a 21-day cycle. Cohort 3: 40 mg dose given on Days 1, 5, 9, and 12 of a 21-day cycle. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met.

Intervention: LY2090314 (Drug)

Outcomes

Primary Outcomes

Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)

Time Frame: Baseline through study completion [Cycle 9 plus 30 days post last dose (21-day or 28 day cycles)]

Drug-related events were defined as treatment-emergent serious and other non-serious AEs that were considered by the investigator to be related to study drug. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

Secondary Outcomes

  • Number of Participants With Best Response of Complete Response or Partial Response(Baseline to progressive disease (up to Cycle 9, 21-day or 28 day cycles))
  • Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time 0 to 8 Hours (h) Postdose [AUC(0-8)](Cycle 1: D1 and/or D9 and/or D15 [predose, 30 minutes (during infusion), up to 24 h after infusion started (1 h, 2 h, 4 h, 6 h, 8 h, and 24 h)])
  • Percent Change From Predose Beta (β)-Catenin Levels(Cycle 1: D1 and D9 (predose, 1 h, 2 h, 4 h, 8 h, and 24 h after infusion started); Cycle 1: D5, D8, and D12 and C2 through C9: D1 (predose, 2 h after infusion started); Cycle 1: D15 (predose, 1 h, 2 h, 4 h, and 8 h after infusion started))
  • Percentage of Participants With Best Response of Complete Response or Partial Response(Baseline to progressive disease (up to Cycle 9, 21-day or 28 day cycles))
  • PK: AUC From Time 0 to Infinity [AUC(0-inf)](Cycle 1: D1 and/or D9 and/or D15 [predose, 30 minutes (during infusion), up to 24 h after infusion started (1 h, 2 h, 4 h, 6 h, 8 h, and 24 h)])
  • PK: Maximum Concentration (Cmax)(Cycle 1: D1 and/or D9 and/or D15 [predose, 30 minutes (during infusion), up to 24 h after infusion started (1 h, 2 h, 4 h, 6 h, 8 h, and 24 h)])
  • Number of Participants Who Died(Baseline through study completion [Cycle 9 plus 30 days post last dose (21-day or 28 day cycles)])

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor TherapyArthritis, Rheumatoid
NCT00689728Eli Lilly and Company100
Completed
Phase 1
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.Relapsed or Refractory Multiple Myeloma
NCT00708292Novartis Pharmaceuticals29
Active, not recruiting
Phase 1
Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had DiseaseProgression on Sorafenib or Are Not Eligible to Receive Sorafenib - NDMedDRA version: 13.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatocellular Carcinoma
EUCTR2010-022338-10-ITEli Lilly and Company204
Active, not recruiting
Not Applicable
Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had Disease Progression on Sorafenib or Are Not Eligible to Receive SorafenibEstudio en fase 2 aleatorizado de LY2157299 en pacientes con carcinoma hepatocelular que han presentado progresión de la enfermedad con sorafenib o no son aptos para recibir sorafenibcarcinoma hepatocelularMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrent
EUCTR2010-022338-10-ESilly S.A.183
Unknown
Not Applicable
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic CancerEffectiveness，Safety，Thymic Cancer
NCT04975061Shanghai YingLi Pharmaceutical Co. Ltd.58